Home LiteratureArticle Details
PMID: 8970964 Published · ppublish English Journal Article

Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.

Journal of virology ·Vol. 70 ·No. 12 ·1996-12-00 ·Pages 8431-7

Watkins BA, Buge S, Aldrich K, Davis AE, Robinson J, Reitz MS, Robert-Guroff M

Abstract

The ability of human immunodeficiency virus type 1 (HIV-1) to replicate in the presence of strong immune responses to the virus may be due to its high mutation rate, which provides envelope gene variability for selection of neutralization-resistant variants. Understanding neutralization escape mechanisms is therefore important for the design of HIV-1 vaccines and our understanding of the disease process. In this report, we analyze mutations at amino acid positions 281 and 582 in the HIV-1 envelope, where substitutions confer resistance to broadly reactive neutralizing antisera from seropositive individuals. Neither of these mutations lies within an antibody-binding site, and therefore the mechanism of immune escape in both cases is by alteration of the shape of the envelope proteins. The conformation of the CD4-binding site is shown to be critical with regard to presentation of other discontinuous epitopes. From our analysis of the neutralization of these variants, we conclude that escape from polyclonal sera occurs through alterations at several different epitopes, generally resulting from single amino acid substitutions which influence envelope conformation. Experiments on a double mutant showed that the combination of both mutations is not additive, suggesting that these variants utilized alternate pathways to elicit similar alterations of the HIV-1 envelope structure.

MeSH Terms
Animals Binding Sites, Antibody CD4 Antigens/immunology COS Cells Epitopes/genetics,immunology Genetic Variation HIV Antibodies/immunology HIV Antigens/genetics,immunology HIV Envelope Protein gp120/genetics,immunology HIV Envelope Protein gp41/genetics,immunology HIV Infections/blood,immunology HIV-1/genetics,immunology,isolation & purification Humans Neutralization Tests Point Mutation Tumor Cells, Cultured
Chemicals
CD4 Antigens Epitopes HIV Antibodies HIV Antigens HIV Envelope Protein gp120 HIV Envelope Protein gp41
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Watkins B A
Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland 20892, USA.
Buge S
Aldrich K
Davis A E
Robinson J
Reitz M S
Robert-Guroff M
References (51)
51 references, click to expand
  1. A molecular clone of HTLV-III with biological activity.
    Nature. 1985 Jul 18-24;316(6025):262-5 PMID: 2410792
  2. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.
    J Virol. 1992 Sep;66(9):5635-41 PMID: 1380099
  3. Induction of anti-HIV neutralizing antibodies by synthetic peptides.
    EMBO J. 1986 Nov;5(11):3065-71 PMID: 3466790
  4. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.
    Proc Natl Acad Sci U S A. 1986 Dec;83(24):9709-13 PMID: 2432599
  5. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.
    Science. 1988 Feb 26;239(4843):1021-3 PMID: 2830667
  6. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6 PMID: 2450351
  7. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  8. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
    J Virol. 1988 Jun;62(6):2107-14 PMID: 2452899
  9. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82 PMID: 2454471
  10. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.
    Cell. 1988 Jul 1;54(1):57-63 PMID: 2838179
  11. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide.
    Virology. 1988 Jul;165(1):209-15 PMID: 2838959
  12. Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120.
    J Virol. 1989 Sep;63(9):3595-600 PMID: 2547987
  13. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72 PMID: 2771954
  14. Characterization of HIV-1 neutralization escape mutants.
    AIDS. 1989 Dec;3(12):777-84 PMID: 2483618
  15. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.
    AIDS. 1990 Feb;4(2):107-12 PMID: 2328092
  16. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.
    AIDS. 1990 Apr;4(4):297-305 PMID: 2190604
  17. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual.
    J Immunol. 1990 Jun 15;144(12):4641-7 PMID: 1693639
  18. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.
    J Virol. 1990 Jul;64(7):3240-8 PMID: 2352323
  19. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
    Science. 1990 Dec 14;250(4987):1590-3 PMID: 1703322
  20. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.
    J Immunol. 1991 Jun 15;146(12):4325-32 PMID: 1710248
  21. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.
    J Virol. 1991 Nov;65(11):6188-93 PMID: 1717717
  22. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949-52 PMID: 1717992
  23. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
    Science. 1991 Oct 4;254(5028):105-8 PMID: 1718036
  24. Antigenic diversity thresholds and the development of AIDS.
    Science. 1991 Nov 15;254(5034):963-9 PMID: 1683006
  25. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.
    J Virol. 1992 Dec;66(12):7538-42 PMID: 1433529
  26. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    J Virol. 1993 Feb;67(2):863-75 PMID: 7678308
  27. Characterization of a neutralizing monoclonal antibody to the external glycoprotein of HIV-1.
    Intervirology. 1992;34(2):86-93 PMID: 1284059
  28. HIV-1 neutralization directed to epitopes other than linear V3 determinants.
    AIDS. 1991;5 Suppl 2:S135-43 PMID: 1726953
  29. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.
    J Virol. 1993 Jun;67(6):3674-9 PMID: 8497077
  30. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
    J Virol. 1993 Jul;67(7):3978-88 PMID: 7685405
  31. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.
    J Virol. 1993 Aug;67(8):4785-96 PMID: 7687303
  32. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Virology. 1993 Sep;196(1):332-7 PMID: 8356803
  33. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
    J Virol. 1993 Oct;67(10):6136-51 PMID: 7690418
  34. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  35. Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.
    J Virol. 1993 Dec;67(12):7493-500 PMID: 7693973
  36. Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker.
    J Biol Chem. 1993 Dec 5;268(34):25894-901 PMID: 7503990
  37. A rapid method for site-specific mutagenesis using larger plasmids as templates.
    Biotechniques. 1993 Oct;15(4):700-4 PMID: 8251172
  38. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.
    J Virol. 1994 Feb;68(2):674-80 PMID: 7507184
  39. Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.
    J Virol. 1994 Feb;68(2):974-8 PMID: 7507188
  40. Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120.
    J Virol. 1994 Apr;68(4):2503-12 PMID: 8139032
  41. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1994 Nov;68(11):6836-47 PMID: 7933065
  42. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
    J Virol. 1994 Dec;68(12):8312-20 PMID: 7525987
  43. Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions.
    J Virol. 1995 Mar;69(3):1860-7 PMID: 7853527
  44. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  45. Antigenic analysis of HIV type 1 external envelope (Env) glycoprotein C2 region: implication for the structure of Env.
    AIDS Res Hum Retroviruses. 1995 Oct;11(10):1177-86 PMID: 8573373
  46. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.
    J Virol. 1996 Mar;70(3):1863-72 PMID: 8627711
  47. Using PCR for rapid site-specific mutagenesis in large plasmids.
    Methods Mol Biol. 1996;57:217-27 PMID: 8850008
  48. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
    J Virol. 1992 Feb;66(2):848-56 PMID: 1370558
  49. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    J Virol. 1992 Mar;66(3):1823-31 PMID: 1637373
  50. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells.
    Science. 1992 Jun 19;256(5064):1687-90 PMID: 1609280
  51. In vitro generation of an HTLV-III variant by neutralizing antibody.
    J Immunol. 1986 Nov 15;137(10):3306-9 PMID: 3639908
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1996-12-00
Pages
8431-7
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC190932
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]